Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Sandostatin LAR alone or combined with pegvisomant or cabergoline in inadequately controlled acromegaly
2005-005852-42Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2007
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of octreotide, pegvisomant and cabergoline in acromegaly (3 arms), sponsored by Novartis. Primary endpoint: Complete response rate. Started Jul 2007; status: completed.
02
Drugs
octreotidepegvisomantcabergoline
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2005-005852-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005852-42.